Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.69)
# 3,324
Out of 4,979 analysts
31
Total ratings
50%
Success rate
-6.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $77 → $89 | $77.69 | +14.56% | 3 | Aug 8, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $50 → $20 | $2.59 | +672.20% | 3 | Jul 8, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.33 | +114.59% | 1 | Apr 29, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $204 → $205 | $210.42 | -2.58% | 3 | Apr 28, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $9.77 | +135.41% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $1.64 | +265.85% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $767.00 | -7.95% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $17.64 | +863.72% | 9 | Nov 7, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $5.51 | +262.98% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $141.21 | +45.88% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.13 | +932.86% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.68 | +273.13% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $29.68 | +102.16% | 1 | Oct 5, 2022 |
Mirum Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $77 → $89
Current: $77.69
Upside: +14.56%
Jasper Therapeutics
Jul 8, 2025
Maintains: Outperform
Price Target: $50 → $20
Current: $2.59
Upside: +672.20%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.33
Upside: +114.59%
AbbVie
Apr 28, 2025
Maintains: Outperform
Price Target: $204 → $205
Current: $210.42
Upside: -2.58%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $9.77
Upside: +135.41%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $1.64
Upside: +265.85%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $767.00
Upside: -7.95%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $17.64
Upside: +863.72%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.51
Upside: +262.98%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $141.21
Upside: +45.88%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.13
Upside: +932.86%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.68
Upside: +273.13%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $29.68
Upside: +102.16%